TARSUS PHARMACEUTICALS, INC. Operating Cash Flow
TARSUS PHARMACEUTICALS, INC. (TARS) reported Operating Cash Flow of $36.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $61.22M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$24.65M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $19.33M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $18.26M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$12.45M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$83.03M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$117.49M.
- TARSUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$49.03M, a 1408.16% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $61.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $36.57M 10-Q · filed 2026-08-06 | $55.90M derived: sum of 3 quarters · filed 2026-08-06 | $74.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$24.65M 10-Q · filed 2026-05-06 | -$5.32M derived: sum of 2 quarters · filed 2026-05-06 | $12.94M derived: sum of 3 quarters · filed 2026-05-06 | -$16.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $37.59M derived: sum of 2 quarters · filed 2026-02-23 | $8.20M derived: sum of 3 quarters · filed 2026-08-06 | -$12.45M 10-K · filed 2026-02-23 |
| 2025-09-30 | $18.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$11.13M derived: sum of 2 quarters · filed 2026-08-06 | -$31.78M 10-Q · filed 2025-11-04 | -$53.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$29.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$50.04M 10-Q · filed 2026-08-06 | -$72.22M derived: sum of 3 quarters · filed 2026-08-06 | -$80.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$20.65M 10-Q · filed 2026-05-06 | -$42.83M derived: sum of 2 quarters · filed 2026-05-06 | -$51.48M derived: sum of 3 quarters · filed 2026-05-06 | -$65.89M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$22.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$30.83M derived: sum of 2 quarters · filed 2026-02-23 | -$45.24M derived: sum of 3 quarters · filed 2026-02-23 | -$83.03M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$8.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$23.06M derived: sum of 2 quarters · filed 2025-11-04 | -$60.84M 10-Q · filed 2025-11-04 | -$100.18M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$14.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$52.19M 10-Q · filed 2025-08-06 | -$91.53M derived: sum of 3 quarters · filed 2026-02-23 | -$123.89M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$37.79M 10-Q · filed 2025-05-01 | -$77.12M derived: sum of 2 quarters · filed 2026-02-23 | -$109.49M derived: sum of 3 quarters · filed 2026-02-23 | -$133.31M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$39.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$71.70M derived: sum of 2 quarters · filed 2026-02-23 | -$95.52M derived: sum of 3 quarters · filed 2026-02-23 | -$117.49M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$32.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$56.19M derived: sum of 2 quarters · filed 2024-11-13 | -$78.16M 10-Q · filed 2024-11-13 | -$89.03M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$23.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$45.80M 10-Q · filed 2024-08-08 | -$56.67M derived: sum of 3 quarters · filed 2025-02-25 | -$75.28M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$21.97M 10-Q · filed 2024-05-08 | -$32.84M derived: sum of 2 quarters · filed 2025-02-25 | -$51.45M derived: sum of 3 quarters · filed 2025-02-25 | -$55.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$10.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$29.48M derived: sum of 2 quarters · filed 2025-02-25 | -$33.74M derived: sum of 3 quarters · filed 2025-02-25 | -$49.03M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$18.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$22.87M derived: sum of 2 quarters · filed 2023-11-09 | -$38.16M 10-Q · filed 2023-11-09 | -$50.28M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$4.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$19.55M 10-Q · filed 2023-08-10 | -$31.67M derived: sum of 3 quarters · filed 2023-08-10 | -$24.55M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$15.29M 10-Q · filed 2023-05-09 | -$27.41M derived: sum of 2 quarters · filed 2023-05-09 | -$20.30M derived: sum of 3 quarters · filed 2023-05-09 | $256.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$12.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$5.01M derived: sum of 2 quarters · filed 2023-03-17 | $15.54M derived: sum of 3 quarters · filed 2023-03-17 | $3.75M 10-K · filed 2023-03-17 |
| 2021-09-30 | $7.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $27.66M derived: sum of 2 quarters · filed 2022-11-09 | $15.87M 10-Q · filed 2022-11-09 | $5.86M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $20.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $8.76M 10-Q · filed 2022-08-11 | -$1.26M derived: sum of 3 quarters · filed 2022-08-11 | -$7.83M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$11.79M 10-Q · filed 2022-05-11 | -$21.81M derived: sum of 2 quarters · filed 2022-05-11 | -$28.38M derived: sum of 3 quarters · filed 2022-05-11 | -$30.94M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$16.59M derived: sum of 2 quarters · filed 2022-03-14 | -$19.14M derived: sum of 3 quarters · filed 2022-03-14 | -$21.14M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$6.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$9.13M derived: sum of 2 quarters · filed 2021-11-10 | -$11.13M 10-Q · filed 2021-11-10 | -$11.93M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$4.55M 10-Q · filed 2021-08-05 | -$5.36M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$2.00M 10-Q · filed 2021-05-11 | -$2.80M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$806.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$3.67M 10-K · filed 2021-03-31 | ||
| 2019-09-30 | -$2.87M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |